ASCO24 Updates: Next-Gen Therapy PH-762 for Skin Cancers

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Mary Spellman, acting Chief medical officer of Phio Pharmaceutical, shared insights from their poster on “INTASYL PH-762: PD-1 intratumoral immunotherapy for cutaneous carcinoma”

I’m Mary Spellman. I’m the acting chief medical officer for FIO Pharmaceuticals. FIO is developing PH762, an intestinal compound that’s designed to silence PD-1 mRNA.

In our clinical study of PH762, we’re enrolling patients who have cutaneous squamous cell carcinomas, metastatic melanoma, or metastatic Merkel cell carcinoma. The patients will be treated every week with an intratumoral injection of PH762, and followed two weeks thereafter with excision of the tumor and assessment of biomarkers and tumor reduction by rhesus criteria. The study is ongoing with one of five dose concentrations studied, and we are moving into the second dose cohort.

To date, the product has been safe and well-tolerated. There have been no serious adverse events, no adverse events of special interests, or immune-related adverse events. We look forward to continuing to enroll this study and assess PH762 for the treatment of cutaneous carcinomas.

More videos and content from ASCO 2024 on OncoDaily.